That would slow the growth of the government’s spending on obesity drugs even as more people on Medicare started using them.
New prices for the 10 drugs in the first round of price negotiations were announced last summer. Those prices will go into effect next year.
Drugmakers were relieved that those cuts were not deeper. They have sued, unsuccessfully, to block the price negotiation program.
Drugs Selected for Medicare’s Second Round of Price Negotiations
Prices will go into effect in 2027.
1. Ozempic, Rybelsus and Wegovy, for diabetes and obesity, from Novo Nordisk
2. Trelegy Ellipta, for lung conditions, from GSK
3. Xtandi, for prostate cancer, from Astellas Pharma and Pfizer
4. Pomalyst, for blood cancer, from Bristol Myers Squibb
5. Ibrance, for breast cancer, from Pfizer
6. Ofev, for lung conditions, from Boehringer Ingelheim
7. Linzess, for gastrointestinal conditions, from AbbVie and Ironwood Pharmaceuticals
8. Calquence, for blood cancers, from AstraZeneca
9. Austedo and Austedo XR, for neurological diseases, from Teva Pharmaceuticals
10. Breo Ellipta, for lung conditions, from GSK
11. Tradjenta, for diabetes, from Boehringer Ingelheim
12. Xifaxan, for liver and gastrointestinal problems, from Salix Pharmaceuticals
13. Vraylar, for depression, from AbbVie
14. Janumet and Janumet XR, for diabetes, from Merck
15. Otezla, for inflammatory conditions, from Amgen